Dermapharm acquires Merck subsidiary Allergopharma

Munich / Rein­bek — P+P Pöllath + Part­ners has advi­sed Derm­a­ph­arm Holding SE on the acqui­si­tion of Aller­g­o­pharma GmbH & Co KG, a subsi­diary of Merck KGaA, based in Rein­bek near Hamburg. Through Derm­a­ph­arm Betei­li­gungs GmbH, the company acqui­res 100% of the shares in the Merck subsidiary.

The tran­sac­tion is still subject to appr­oval by the rele­vant regu­la­tory autho­rity; closing is expec­ted by the end of the second quar­ter of 2020.

Derm­a­ph­arm Holding SE, head­quar­te­red in Grün­wald, Germany, focu­ses on the produc­tion and distri­bu­tion of high-quality derma­to­lo­gi­cal and aller­go­lo­gi­cal phar­maceu­ti­cals. Aller­g­o­pharma is a company specia­li­zed in desen­si­tiza­tion for allergies.

P+P Pöllath + Part­ners provi­ded compre­hen­sive legal advice to Derm­a­ph­arm Holding SE in connec­tion with the acqui­si­tion with the follo­wing multi­di­sci­pli­nary and multi­site team:

Dr. Matthias Bruse, LL.M., Photo (Part­ner, Lead Part­ner, Corporate/M&A, Munich)
Daniel Wied­mann, LL.M. (Asso­cia­ted Part­ner, Anti­trust Law, Frankfurt)
Dr. Matthias Werner (Coun­sel, Real Estate, Berlin)
Chris­tine Funk, LL.M. (Senior Asso­ciate, IP/M&A, Frankfurt)
Jasmin Wagner (Senior Asso­ciate, Corporate/M&A, Munich)
Dr. Jesko von Mirbach, LL.M., EMBA (Asso­ciate, Corporate/M&A, Berlin)
Dr. Lena Hummel (Asso­ciate, Corporate/M&A, Munich)